Inventor
MAJETI RAVINDRA
US45 patents
⚠️ This page may combine multiple inventors who share the name “MAJETI RAVINDRA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV LELAND STANFORD JUNIOR
42 patentsUS9382320B2Jul 5, 2016
Humanized and chimeric monoclonal antibodies to CD47
UNIV LELAND STANFORD JUNIOR36 citations98
US9017675B2Apr 28, 2015
Humanized and chimeric monoclonal antibodies to CD47
UNIV LELAND STANFORD JUNIOR66 citations98
US8361736B2Jan 29, 2013
Ex vivo methods for targeting or depleting acute myeloid leukemia cancer stem cells
UNIV LELAND STANFORD JUNIOR50 citations98
US9623079B2Apr 18, 2017
Methods for achieving therapeutically effective doses of anti-CD47 agents for treating cancer
UNIV LELAND STANFORD JUNIOR26 citations97
US9493575B2Nov 15, 2016
Methods for manipulating phagocytosis mediated by CD47
UNIV LELAND STANFORD JUNIOR48 citations97
US9399682B2Jul 26, 2016
Methods for manipulating phagocytosis mediated by CD47
UNIV LELAND STANFORD JUNIOR38 citations97
US8709429B2Apr 29, 2014
Markers of acute myeloid leukemia stem cells
UNIV LELAND STANFORD JUNIOR30 citations96
US11136391B2Oct 5, 2021
Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody
UNIV LELAND STANFORD JUNIOR9 citations93
US9796781B2Oct 24, 2017
Markers of acute myeloid leukemia stem cells
UNIV LELAND STANFORD JUNIOR16 citations93
US9193955B2Nov 24, 2015
Markers of acute myeloid leukemia stem cells
UNIV LELAND STANFORD JUNIOR10 citations93
US10301387B2May 28, 2019
Methods for achieving therapeutically effective doses of anti-CD47 agents
UNIV LELAND STANFORD JUNIOR11 citations92
US9765143B2Sep 19, 2017
Methods for manipulating phagocytosis mediated by CD47
UNIV LELAND STANFORD JUNIOR17 citations92
US9624305B2Apr 18, 2017
Methods of manipulating phagocytosis mediated by CD47
UNIV LELAND STANFORD JUNIOR17 citations92
US9611329B2Apr 4, 2017
Methods of manipulating phagocytosis mediated by CD47
UNIV LELAND STANFORD JUNIOR19 citations92
US9605076B2Mar 28, 2017
Methods of manipulating phagocytosis mediated by CD47
UNIV LELAND STANFORD JUNIOR19 citations92
US11141480B2Oct 12, 2021
Dosing parameters for CD47 targeting therapies to hematologic malignancies
UNIV LELAND STANFORD JUNIOR9 citations86
US11377495B2Jul 5, 2022
Markers of acute myeloid leukemia stem cells
UNIV LELAND STANFORD JUNIOR7 citations85
US11518806B2Dec 6, 2022
Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody
UNIV LELAND STANFORD JUNIOR6 citations84
US11072655B2Jul 27, 2021
Markers of acute myeloid leukemia stem cells
UNIV LELAND STANFORD JUNIOR6 citations84
US10662242B2May 26, 2020
Markers of acute myeloid leukemia stem cells
UNIV LELAND STANFORD JUNIOR6 citations84
US11603404B2Mar 14, 2023
Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody
UNIV LELAND STANFORD JUNIOR3 citations83
US11807684B2Nov 7, 2023
Humanized and chimeric monoclonal antibodies to CD47
UNIV LELAND STANFORD JUNIOR1 citations73
US10995152B2May 4, 2021
Modified immunoglobulin hinge regions to reduce hemagglutination
UNIV LELAND STANFORD JUNIOR2 citations73
US10087257B2Oct 2, 2018
SIRP alpha-antibody fusion proteins
UNIV LELAND STANFORD JUNIOR3 citations71
US11773165B2Oct 3, 2023
Markers of acute myeloid leukemia stem cells
UNIV LELAND STANFORD JUNIOR0 citations63
US11760800B2Sep 19, 2023
Markers of acute myeloid leukemia stem cells
UNIV LELAND STANFORD JUNIOR0 citations63
US11760810B2Sep 19, 2023
Modified immunoglobulin hinge regions to reduce hemagglutination
UNIV LELAND STANFORD JUNIOR0 citations63
US11014985B2May 25, 2021
Humanized and chimeric monoclonal antibodies to CD47
UNIV LELAND STANFORD JUNIOR0 citations63
US12274746B2Apr 15, 2025
Dosing parameters for CD47 targeting therapies to hematologic malignancies
UNIV LELAND STANFORD JUNIOR0 citations62
US12258399B2Mar 25, 2025
Methods for achieving therapeutically effective doses of anti-CD47 agents
UNIV LELAND STANFORD JUNIOR0 citations62
US12162939B2Dec 10, 2024
Methods for manipulating phagocytosis mediated by CD47
UNIV LELAND STANFORD JUNIOR0 citations62
US11780918B2Oct 10, 2023
Markers of acute myeloid leukemia stem cells
UNIV LELAND STANFORD JUNIOR0 citations62
US11718670B2Aug 8, 2023
Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer
UNIV LELAND STANFORD JUNIOR0 citations62
US11472878B2Oct 18, 2022
Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer
UNIV LELAND STANFORD JUNIOR0 citations62
US11104731B2Aug 31, 2021
Compositions for achieving therapeutically effective doses of anti-CD47 agents
UNIV LELAND STANFORD JUNIOR0 citations62
US12258403B2Mar 25, 2025
Methods for treating myeloma by achieving therapeutically effective doses of anti-CD47 antibody
UNIV LELAND STANFORD JUNIOR0 citations61
US12194093B2Jan 14, 2025
Dosing parameters for CD47 targeting therapies to hematologic malignancies
UNIV LELAND STANFORD JUNIOR0 citations61
US10487150B2Nov 26, 2019
SIRP alpha-antibody fusion proteins
UNIV LELAND STANFORD JUNIOR1 citations61
US10942185B2Mar 9, 2021
Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptor
UNIV LELAND STANFORD JUNIOR0 citations58
US12371469B2Jul 29, 2025
Therapeutic antigen binding proteins specific for CD93 and methods of use thereof
UNIV LELAND STANFORD JUNIOR0 citations55
US10640561B2May 5, 2020
Methods for manipulating phagocytosis mediated by CD47
UNIV LELAND STANFORD JUNIOR0 citations52
US10040862B2Aug 7, 2018
Humanized and chimeric monoclonal antibodies to CD99
UNIV LELAND STANFORD JUNIOR1 citations52